<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27816" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Propofol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Folino</surname>
            <given-names>Thomas B.</given-names>
          </name>
          <aff>NYU LANGONE</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muco</surname>
            <given-names>Erind</given-names>
          </name>
          <aff>Campbell University School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Safadi</surname>
            <given-names>Anthony O.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parks</surname>
            <given-names>Lance J.</given-names>
          </name>
          <aff>West Virginia University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thomas Folino declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Erind Muco declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anthony Safadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lance Parks declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27816.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Propofol is an intravenous anesthetic used for procedural sedation, during monitored anesthesia care, or as an induction agent for general anesthesia. It may be administered as a bolus or an infusion, or some combination of the two. Propofol is prepared in a lipid emulsion which gives it the characteristic milky white appearance. Strict aseptic technique must be used when drawing up propofol as the emulsion can support microbial growth. It has both approved and off-label uses. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, monitoring, and toxicity of propofol, so providers can direct patient anesthesia where it is indicated, as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of propofol.</p></list-item><list-item><p>Summarize the approved and off-label indications for using propofol.</p></list-item><list-item><p>Review the appropriate monitoring and toxicity of propofol.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance propofol where it is indicated and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27816&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27816">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27816.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Propofol is an intravenous anesthetic used for procedural sedation, during monitored anesthesia care, or as an induction agent for general anesthesia. It may be&#x000a0;administered as a bolus or an infusion, or some combination of the two. Propofol is prepared in a lipid emulsion which gives it the characteristic milky white appearance and the colloquial name "milk of amnesia." The formula contains soybean oil, glycerol, egg lecithin, and a small amount of the preservative EDTA. Strict aseptic technique must be used when drawing up propofol as the emulsion can support microbial growth.<xref ref-type="bibr" rid="article-27816.r1">[1]</xref><xref ref-type="bibr" rid="article-27816.r2">[2]</xref><xref ref-type="bibr" rid="article-27816.r3">[3]</xref></p>
        <p>
<bold>Clinical uses of Propofol</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Induction of general anesthesia in patients &#x02265; three years old, though it may be used as an induction agent if a child less than three years of age has IV access.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Maintenance of anesthesia in patients &#x0003e; 2 months old</p>
          </list-item>
          <list-item>
            <p>Sedation during monitored anesthesia care for patients undergoing procedures</p>
          </list-item>
          <list-item>
            <p>Sedation in intubated, mechanically-ventilated ICU patients</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label uses of Propofol</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Status Epilepticus, refractory (children and adults)</p>
          </list-item>
          <list-item>
            <p>Treatment of refractory postoperative nausea and vomiting</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27816.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Like most general anesthetic agents, the mechanism of action for propofol is poorly understood but thought to be related to the effects on GABA-mediated chloride channels in the brain. Propofol may work by decreasing the dissociation of GABA from GABA receptors in the brain and potentiating the inhibitory effects of the neurotransmitter. This, in turn, keeps the channel activated for a longer duration resulting in an increase in chloride conductance across the neuron, causing a hyper-polarization of the cell membrane, making it harder for a successful action potential to fire.<xref ref-type="bibr" rid="article-27816.r4">[4]</xref></p>
      </sec>
      <sec id="article-27816.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Pharmacodynamics&#x000a0;and Pharmacokinetics</bold>
</p>
        <p><bold>Route of Administration:</bold> Intravenous&#x000a0;</p>
        <p><bold>Onset of action:</bold> Propofol has a rapid onset of action that is dose-dependent and less than a minute.</p>
        <p><bold>Duration of action:</bold> An induction dose of propofol will have a clinical effect for approximately 10 minutes. The prolonged or repeated administration will accumulate in peripheral tissues and will cause an increased duration of action.&#x000a0;</p>
        <p><bold>Distribution:</bold> Large volume of distribution.</p>
        <p><bold>Protein Binding:</bold> 97% to 99%.</p>
        <p><bold>Metabolism:</bold> Hepatic oxidation and conjugation to sulfate and glucuronide conjugates.</p>
        <p><bold>Clearance:</bold> Hepatic clearance is approximately 60%, with extrahepatic clearance making up the remaining 40%, most of which is via the kidneys.</p>
        <p><bold>Half-life:</bold> Propofol is bi-phasic, with its initial half-life being relatively quick, around 40 minutes, and its terminal half-life usually being 4 to 7 hours. Context-sensitive half-time may be up to 1&#x000a0;to 3 days after a 10-day infusion. The clinical effect of propofol is much shorter in duration.</p>
        <p><bold>Excretion:</bold> Primarily renal.</p>
        <p>After a single bolus or short-term infusion, the termination of action is primarily by redistribution, owing to the lipophilicity of the drug. Metabolism and excretion play minor roles in the termination of effects following a single bolus. Prolonged infusions may lead to slower emergence from anesthesia once the tissues and blood have reached a steady-state concentration.<xref ref-type="bibr" rid="article-27816.r5">[5]</xref></p>
      </sec>
      <sec id="article-27816.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Transient local pain at the injection site is the most common adverse reaction. This may be decreased by administering IV lidocaine before propofol bolus.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Myoclonus</p>
          </list-item>
          <list-item>
            <p>Occasionally has been seen to cause EKG changes (QT interval prolongation). This is rarely clinically significant.</p>
          </list-item>
          <list-item>
            <p>Discolored urine (a green tint); this adverse event is exceedingly rare<xref ref-type="bibr" rid="article-27816.r6">[6]</xref><xref ref-type="bibr" rid="article-27816.r7">[7]</xref><xref ref-type="bibr" rid="article-27816.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>Propofol is safe for use in pregnancy but will cross the placenta and may be associated with neonatal CNS and respiratory depression. It is the drug of choice for induction of general anesthesia in the stable obstetric patient and the lowest risk class of all of the induction agents currently used.<xref ref-type="bibr" rid="article-27816.r9">[9]</xref></p>
        <p>Propofol was formerly listed as a Category B drug for use in pregnancy. However, in late 2014 the FDA removed the lettering system to denote the degree of potential harm in pregnancy or lactation and moved to a more descriptive system based on the individual effects of pharmacologic agents.</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Propofol may potentiate other medications that cause CNS or respiratory depression and a decrease in blood pressure. Caution is advised when using other agents that may prolong the QT interval. Propofol has weak CYP3A4 inhibitory effects but is unlikely to be of clinical concern.<xref ref-type="bibr" rid="article-27816.r10">[10]</xref></p>
      </sec>
      <sec id="article-27816.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Propofol is contraindicated in any patient that has any known hypersensitivity reaction to the drug. Caution&#x000a0;is necessary for any patient with abnormally low blood pressure.<xref ref-type="bibr" rid="article-27816.r11">[11]</xref></p>
        <p>Some package inserts state that propofol should not be given to those with reported allergies to eggs, egg products, soy, or soy products. An allergic reaction occurs secondary to exposure to specific proteins from both egg and soy sources and not the fats (lecithin and oil, respectively) that make up the emulsion. The oils used to manufacture propofol are unlikely to contain quantities of proteins significant enough to produce an allergic cross-reaction.&#x000a0; That being said, patients with atopy have been reported to have a higher incidence of an allergic reaction to many medications, and there are case reports of cross-sensitivity to propofol in the atopic patient. Clinical judgment should be exercised on a case-to-case basis.&#x000a0;</p>
      </sec>
      <sec id="article-27816.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Therapeutic Effects of Propofol</bold>
</p>
        <p>When administered as a bolus, propofol has a rapid and smooth onset that is extremely predictable in its duration. It has low organ toxicity and is very compatible with a wide range of other commonly used drugs in the setting of anesthesia.<xref ref-type="bibr" rid="article-27816.r12">[12]</xref></p>
        <p>
<bold>Central Nervous System Effects</bold>
</p>
        <p>Propofol causes a dose-dependent decreased level of consciousness and can be used for moderate sedation to general anesthesia. This decreased sensorium may lead to loss of protective airway reflexes, and propofol should not be used in any patient unless they are appropriately fasting. The American Society of Anesthesiologists' (ASA) NPO guidelines should be used as a template for the duration of fast following varying oral intake.&#x000a0;</p>
        <p>In addition to depression of cognition, propofol will cause a decrease in cerebral blood flow, intracranial pressure, and cerebral oxygen consumption. Propofol causes increased latency and decreased amplitude during somatosensory evoked potential monitoring and, at higher doses, can lead to burst suppression and even an isoelectric EEG. In rat models, propofol has neuroprotective effects on the brain and will decrease oxidative damage and apoptosis.&#x000a0;</p>
        <p>It also has been shown to cause transient excitatory phenomena such as choreiform movements and opisthotonus (abnormal posturing caused by spasm of the muscles) after injection. Propofol has also been shown to suppress seizure activity in the brain and is seldom used off-label to treat refractory status epilepticus.</p>
        <p>Propofol exerts antiemetic actions on the brain, which helps reduce postoperative nausea and vomiting. Although this mechanism is still unknown, it is believed to be due to a direct depressant effect on the chemoreceptor trigger zone and vagal nuclei.</p>
        <p>
<bold>Cardiovascular Effects</bold>
</p>
        <p>Propofol causes vasodilation by inhibiting sympathetic vasoconstrictor activity along with mild depression of myocardial contractility, which accounts for the hypotension often seen when administered. This effect can be substantial with a profound reduction in the mean arterial pressure, especially when propofol is administered as a bolus. Caution should be used in hypovolemic or in catecholamine-depleted patients.<xref ref-type="bibr" rid="article-27816.r13">[13]</xref></p>
        <p>
<bold>Respiratory Effects</bold>
</p>
        <p>Propofol causes dose-dependent respiratory depression due to the inhibition of the hypercapnic ventilatory drive. This respiratory depression is potentiated by concurrent use of other sedative agents (benzodiazepines, opioids, central acting alpha two agonists, or other anesthetic medications). An induction dose of propofol will cause apnea.</p>
        <p>Propofol has also been seen to cause a low incidence of bronchospasm in asthmatic patients.</p>
        <p>
<bold>Additional Monitoring Requirements/Precautions</bold>
</p>
        <p>Propofol can cause profound cardiovascular and respiratory depression and will ultimately end in general anesthesia if given in large enough doses. For this reason, any practitioner who administers propofol must be qualified to care for a patient who is at any level of sedation (ranging from moderate sedation to general anesthesia). Emergency equipment must be readily available and in good working order. At a minimum, the ASA recommends monitoring of oxygenation, circulation, ventilation, and temperature for all anesthetics. Appropriate anesthesia personnel must be continually present during all anesthetic cases requiring general anesthesia, monitored anesthesia care, or a regional anesthetic.&#x000a0;</p>
        <p>Rescue equipment should include a bag valve mask, two sources of oxygen (centrally supplied or cylinders), laryngoscopes, endotracheal tubes of differing sizes, laryngeal mask airways, a crash cart with appropriate ACLS medications, and a defibrillator. The ASA guidelines for NPO status should be followed for any patient receiving an anesthetic since the loss of protective airway reflexes carries the risk of gastric content aspiration.<xref ref-type="bibr" rid="article-27816.r14">[14]</xref></p>
      </sec>
      <sec id="article-27816.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p><bold>Propofol Infusion Syndrome (PRIS):</bold>&#x000a0;This is a rare but serious side effect of prolonged infusion of propofol (usually &#x0003e; 4mg/kg/hour for more than 24 hours). The syndrome presents as metabolic acidosis, hyperkalemia, hyperlipidemia, and rhabdomyolysis and may proceed to renal and cardiac failure and ultimately death.<xref ref-type="bibr" rid="article-27816.r15">[15]</xref></p>
        <p>It is thought to occur due to alterations in mitochondrial metabolism and electron transport chain function, but the exact mechanism of PRIS is still unknown. The onset of PRIS usually occurs within four days of the initial propofol treatment. This syndrome has been noted to occur during prolonged infusions at high doses in pediatric/young adult patients or those with the need for prolonged sedation, such as mechanically ventilated patients with head trauma.</p>
        <p>PRIS is a diagnosis of exclusion. Management of PRIS is the discontinuation of propofol infusion and supportive treatment. Mortality associated with PRIS has been estimated to be around 33% and becomes even higher if the diagnosis is delayed.</p>
      </sec>
      <sec id="article-27816.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Propofol is a widely used induction agent in anesthesia. It is used by the anesthesiologist, nurse anesthetist, and intensivist. All healthcare providers who use this agent should be familiar with its adverse effects. A dedicated member of the anesthesia staff should be in charge of monitoring the patient during induction with propofol. The patient must be hooked up to the cardiac monitors and have an additional IV line in case it is needed to manage the hypotension. The anesthesiologist and nurse should also be familiar with PRIS and how to manage it.<xref ref-type="bibr" rid="article-27816.r16">[16]</xref><xref ref-type="bibr" rid="article-27816.r11">[11]</xref>&#x000a0;A COordinated effort between all procedural team members, including clinicians, specialists, nurses, and surgical assistants, will help drive optimal patient outcomes when using propofol for anesthesia.&#x000a0;</p>
      </sec>
      <sec id="article-27816.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27816&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27816">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27816/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27816">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27816.s11">
        <title>References</title>
        <ref id="article-27816.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smithburger</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic Considerations Surrounding Sedation, Delirium, and Sleep in Critically Ill Adults: A Narrative Review.</article-title>
            <source>J Pharm Pract</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-291</page-range>
            <pub-id pub-id-type="pmid">30955461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus.</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>06</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">30954065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Draheim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Krupp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Breihan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Rourke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a Multidisciplinary Pain, Agitation, and Delirium Guideline in Mechanically Ventilated Critically Ill Adults.</article-title>
            <source>Hosp Pharm</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-124</page-range>
            <pub-id pub-id-type="pmid">30923405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antkowiak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rammes</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>GABA(A) receptor-targeted drug development -New perspectives in perioperative anesthesia.</article-title>
            <source>Expert Opin Drug Discov</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>683</fpage>
            <page-range>683-699</page-range>
            <pub-id pub-id-type="pmid">30912680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Condello</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Santarpino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fiore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Di Bari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Speziale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moscarelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nasso</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Propofol pharmacokinetics and pharmacodynamics-a perspective in minimally invasive extracorporeal circulation.</article-title>
            <source>Interact Cardiovasc Thorac Surg</source>
            <year>2021</year>
            <month>Oct</month>
            <day>04</day>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>625</fpage>
            <page-range>625-627</page-range>
            <pub-id pub-id-type="pmid">33969407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hemphill</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McMenamin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bellamy</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Propofol infusion syndrome: a structured literature review and analysis of published case reports.</article-title>
            <source>Br J Anaesth</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>448</fpage>
            <page-range>448-459</page-range>
            <pub-id pub-id-type="pmid">30857601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haffar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hyder</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Abu Dayyeh</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Bazerbachi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Acute pancreatitis associated with intravenous administration of propofol: evaluation of causality in a systematic review of the literature.</article-title>
            <source>Gastroenterol Rep (Oxf)</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-23</page-range>
            <pub-id pub-id-type="pmid">30792862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Louer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McKinney</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Abu-Sultaneh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lutfi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abulebda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of a Propofol and Ketamine Based Procedural Sedation Protocol in Children with Cerebral Palsy Undergoing Botulinum Toxin A Injections.</article-title>
            <source>PM R</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>12</issue>
            <fpage>1320</fpage>
            <page-range>1320-1325</page-range>
            <pub-id pub-id-type="pmid">30761757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montandrau</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Espitalier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bouyou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laffon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rem&#x000e9;rand</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Thiopental versus propofol on the outcome of the newborn after caesarean section: An impact study.</article-title>
            <source>Anaesth Crit Care Pain Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>631</fpage>
            <page-range>631-635</page-range>
            <pub-id pub-id-type="pmid">30978402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ting</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Drug interaction is the cornerstone of modern anesthesia practice.</article-title>
            <source>Minerva Anestesiol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-225</page-range>
            <pub-id pub-id-type="pmid">30762327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Andolfatto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for Emergency Department Procedural Sedation With Propofol: 2018 Update.</article-title>
            <source>Ann Emerg Med</source>
            <year>2019</year>
            <month>May</month>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>470</fpage>
            <page-range>470-480</page-range>
            <pub-id pub-id-type="pmid">30732981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brohan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goudra</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>The Role of GABA Receptor Agonists in Anesthesia and Sedation.</article-title>
            <source>CNS Drugs</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>845</fpage>
            <page-range>845-856</page-range>
            <pub-id pub-id-type="pmid">29039138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Propofol Inhibits Ischemia/Reperfusion-Induced Cardiotoxicity Through the Protein Kinase C/Nuclear Factor Erythroid 2-Related Factor Pathway.</article-title>
            <source>Front Pharmacol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>655726</fpage>
            <pub-id pub-id-type="pmid">34054535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrier</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Kiely</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luxton</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Propofol detection for monitoring of intravenous anaesthesia: a review.</article-title>
            <source>J Clin Monit Comput</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>315</fpage>
            <page-range>315-323</page-range>
            <pub-id pub-id-type="pmid">34213720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michel-Mac&#x000ed;as</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morales-Barquet</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Reyes-Palomino</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Machuca-Vaca</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Orozco-Guill&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Single dose of propofol causing propofol infusion syndrome in a newborn.</article-title>
            <source>Oxf Med Case Reports</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>2018</volume>
            <issue>6</issue>
            <fpage>omy023</fpage>
            <pub-id pub-id-type="pmid">29942532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27816.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bagshaw</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Practicalities of Total Intravenous Anesthesia and Target-controlled Infusion in Children.</article-title>
            <source>Anesthesiology</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>164</fpage>
            <page-range>164-185</page-range>
            <pub-id pub-id-type="pmid">30920966</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
